Core Insights - The Chongqing Municipal Government has officially issued measures to support the high-quality development of innovative drugs, marking a significant push for the biopharmaceutical industry in the region [1][2] Group 1: Innovative Drug Development - Chongqing has achieved major breakthroughs in innovative drugs, with the launch of the first innovative drug and the first CAR-T cell therapy for children and adolescents [1] - There are currently 42 innovative drug projects in clinical trials in Chongqing, with expectations of 1-3 new drugs being approved annually over the next three years [1][2] Group 2: Support Measures - The newly issued measures include 25 specific initiatives across four main areas: accelerating research and development, optimizing application, clinical collaboration, and ecosystem empowerment [2][3] - A key focus is on creating a priority list for innovative drug research, providing comprehensive support throughout clinical trials, registration, production, and financing [2] Group 3: Clinical Application and Collaboration - Chongqing will establish an "innovative drug application list" to facilitate rapid market access for listed products, ensuring that medical institutions comply with the distribution of innovative drugs [2] - The measures encourage collaboration among pharmaceutical companies, research institutions, and universities to form comprehensive innovation platforms, enhancing clinical research capabilities [3]